These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 33630072)

  • 21. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis.
    Provenzano R; Shutov E; Eremeeva L; Korneyeva S; Poole L; Saha G; Bradley C; Eyassu M; Besarab A; Leong R; Liu CS; Neff TB; Szczech L; Yu KP
    Nephrol Dial Transplant; 2021 Aug; 36(9):1717-1730. PubMed ID: 33629100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis.
    Zheng Q; Yang H; Fu X; Huang Y; Wei R; Wang Y; Liu YN; Liu WJ
    Nephrol Dial Transplant; 2021 Aug; 36(9):1603-1615. PubMed ID: 33051677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis.
    Liu J; Zhang A; Hayden JC; Bhagavathula AS; Alshehhi F; Rinaldi G; Kontogiannis V; Rahmani J
    Pharmacol Res; 2020 May; 155():104747. PubMed ID: 32171893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
    Provenzano R; Tumlin J; Zabaneh R; Chou J; Hemmerich S; Neff TB; Yu KP
    J Clin Pharmacol; 2020 Nov; 60(11):1432-1440. PubMed ID: 32603526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD.
    Pergola PE; Charytan C; Little DJ; Tham S; Szczech L; Leong R; Fishbane S
    Kidney360; 2022 Sep; 3(9):1511-1528. PubMed ID: 36245647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis.
    Zhang L; Hou J; Li J; Su SS; Xue S
    Aging (Albany NY); 2021 Jun; 13(13):17914-17929. PubMed ID: 34115611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients.
    Besarab A; Chernyavskaya E; Motylev I; Shutov E; Kumbar LM; Gurevich K; Chan DT; Leong R; Poole L; Zhong M; Saikali KG; Franco M; Hemmerich S; Yu KH; Neff TB
    J Am Soc Nephrol; 2016 Apr; 27(4):1225-33. PubMed ID: 26494833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
    Chen N; Qian J; Chen J; Yu X; Mei C; Hao C; Jiang G; Lin H; Zhang X; Zuo L; He Q; Fu P; Li X; Ni D; Hemmerich S; Liu C; Szczech L; Besarab A; Neff TB; Peony Yu KH; Valone FH
    Nephrol Dial Transplant; 2017 Aug; 32(8):1373-1386. PubMed ID: 28371815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis.
    Zheng L; Tian J; Liu D; Zhao Y; Fang X; Zhang Y; Liu Y
    Br J Clin Pharmacol; 2022 Mar; 88(3):919-932. PubMed ID: 34428860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Roxadustat for CKD-related Anemia in Non-dialysis Patients.
    Coyne DW; Roger SD; Shin SK; Kim SG; Cadena AA; Moustafa MA; Chan TM; Besarab A; Chou W; Bradley C; Eyassu M; Leong R; Lee TT; Saikali KG; Szczech L; Yu KP
    Kidney Int Rep; 2021 Mar; 6(3):624-635. PubMed ID: 33732977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in Japan.
    Hamano T; Yamaguchi Y; Goto K; Mizokawa S; Ito Y; Dellanna F; Barratt J; Akizawa T
    Adv Ther; 2024 Apr; 41(4):1526-1552. PubMed ID: 38363463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials.
    Hamano T; Yamaguchi Y; Goto K; Martin S; Jiletcovici A; Dellanna F; Akizawa T; Barratt J
    Adv Ther; 2024 Apr; 41(4):1553-1575. PubMed ID: 38363466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
    Barratt J; Sulowicz W; Schömig M; Esposito C; Reusch M; Young J; Csiky B
    Adv Ther; 2021 Oct; 38(10):5345-5360. PubMed ID: 34523074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic Effect of Roxadustat on Patients With Posttransplant Anemia.
    Miki K; Nakamura Y; Yokoyama T; Kamiyama M; Ishii Y
    Transplant Proc; 2022 Apr; 54(3):671-677. PubMed ID: 35256197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients.
    Song J; Chen X; Zhou L; Yu W; Liu H; Yuan F
    J Int Med Res; 2023 Oct; 51(10):3000605231204475. PubMed ID: 37843847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.
    Akizawa T; Yamaguchi Y; Majikawa Y; Reusch M
    Ther Apher Dial; 2021 Oct; 25(5):575-585. PubMed ID: 33200512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical parameters among patients in Japan with anemia and non-dialysis-dependent chronic kidney disease with and without diabetes mellitus who received roxadustat.
    Akizawa T; Tanaka-Amino K; Otsuka T; Yamaguchi Y
    Clin Exp Nephrol; 2022 Sep; 26(9):843-850. PubMed ID: 35462610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
    Barratt J; Dellanna F; Portoles J; Choukroun G; De Nicola L; Young J; Dimković N; Reusch M
    Adv Ther; 2023 Apr; 40(4):1546-1559. PubMed ID: 36749544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on renal anemia in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis.
    Jia L; Dong X; Yang J; Jia R; Zhang H
    Ann Transl Med; 2019 Dec; 7(23):720. PubMed ID: 32042736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal dialysis.
    Wu T; Qi Y; Ma S; Zhang L; Pu X; Chen K; Zhao Y; Sang S; Xiao J
    Ren Fail; 2022 Dec; 44(1):529-540. PubMed ID: 35318873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.